TYRA (Tyra Biosciences) Debt-to-Asset : 0.02 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TYRA Tyra Biosciences Inc TYRA
28 GF Score
Price $25.29
! 2 Warning Signs
View Full Analysis

What is Tyra Biosciences Debt-to-Asset?

Tyra Biosciences TYRA +1.02% 28 Debt-to-Asset is 0.02 as of Jun. 2026. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Tyra Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.50 Mil. Tyra Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $5.08 Mil. Tyra Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $383.36 Mil. Tyra Biosciences's debt to asset for the quarter that ended in Jun. 2026 was 0.01.

Tyra Biosciences  (NAS:TYRA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Tyra Biosciences Debt-to-Asset Related Terms

Tyra Biosciences Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Tyra Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tyra Biosciences Debt-to-Asset Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.00 0.01 0.03 0.02 0.02

Tyra Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.01 0.02

TYRA vs STOK, SNDX, FTRE: Debt-to-Asset Comparison

For the Biotechnology subindustry, Tyra Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyra Biosciences Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's Debt-to-Asset falls into.


TYRA
28GF Score
Tyra Biosciences Inc TYRA
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tyra Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Tyra Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.472 + 5.338) / 282.609
=0.02

Tyra Biosciences's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.504 + 5.078) / 383.362
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.02 mean?
Tyra Biosciences (TYRA) has a Debt-to-Asset of 0.02 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Tyra Biosciences and its competitors.
Is Tyra Biosciences' Debt-to-Asset too high?
Tyra Biosciences' current Debt-to-Asset is 0.02. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Debt-to-Asset compare to STOK and SNDX?
Tyra Biosciences' Debt-to-Asset of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Tyra Biosciences and its competitors. Tyra Biosciences's current Debt-to-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Debt-to-Asset of 0.02. The current Debt-to-Asset is 0.02. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Debt-to-Asset is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tyra Biosciences Business Description

Address 2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score

Get the complete analysis for TYRA

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.29
Price